NASDAQ$AMLX
Amylyx Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Amylyx reported financial results for Q1 2024 and announced strategic updates.
Amylyx Pharmaceuticals reported a net product revenue of $88.6 million for the first quarter of 2024, compared to $71.4 million for the same period in 2023. However, the company experienced a net loss of $118.8 million, or $1.75 per share, compared to a net income of $1.6 million, or $0.02 per share, for the same period in 2023. The company is focusing on key clinical programs and has a cash runway into 2026.
- Amylyx announced formal intention to remove RELYVRIO/ALBRIOZA from the market based on topline results from the Phase 3 PHOENIX trial.
- Interim data from the Phase 2 HELIOS clinical trial of AMX0035 in Wolfram syndrome demonstrated encouraging improvement.
- Interim analysis from the ORION study of AMX0035 in progressive supranuclear palsy is expected in mid-2025.
- Amylyx expects to initiate a clinical trial of AMX0114 in ALS in the second half of 2024.
Headline financials
Revenue & EPS history
Amylyx · Revenue · Quarterly
$88.6M
Forward guidance
Amylyx expects cash runway into 2026, which will allow the organization to deliver on key upcoming milestones, including anticipated data readouts from HELIOS (AMX0035 in Wolfram syndrome), ORION (AMX0035 in PSP), and its planned trial of AMX0114 in ALS.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
+0.3%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+7.4%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+23.4%
Q4 2021
Best reaction
-30.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -7.6% | -9.5% | -2.3% | |
| Q3 2025 | -5.9% | -4.2% | +7.3% | |
| Q1 2025 | -6.0% | -7.8% | +9.4% | |
| Q4 2024 | +0.3% | +29.0% | +17.0% | |
| Q3 2024 | +7.7% | +0.3% | -17.4% | |
| Q2 2024 | +1.1% | +5.9% | +26.1% | |
| Q1 2024 | -8.8% | -3.1% | -8.3% | |
| Q4 2023 | +15.3% | +24.1% | -82.1% | |
| Q3 2023 | -30.7% | -30.4% | -22.2% | |
| Q2 2023 | +0.5% | -2.3% | -4.5% | |
| Q1 2023 | -4.4% | -6.1% | -11.9% | |
| Q4 2022 | +11.2% | -1.2% | -3.9% | |
| Q3 2022 | -1.8% | +2.4% | +3.0% | |
| Q3 2021 | -1.8% | +2.4% | +3.0% | |
| Q2 2021 | -5.5% | -5.7% | +12.7% | |
| Q2 2022 | -5.5% | -5.7% | +12.7% | |
| Q4 2021 | +23.4% | +28.2% | +97.5% | |
| Q1 2022 | +23.4% | +28.2% | +97.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro